Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Part of paid clinical trials in Oakland, California.

Sponsor
Kaiser Permanente
Study ID
NCT05263778
Phase
PHASE4
Status
Unknown

Conditions

  • Cardiovascular Diseases
  • NSTEMI
  • STEMI

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The overall objective of the Cholesterol Lowering via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome ACS (CLEAR ACS) study is to determine the efficacy, safety, and tolerability of bempedoic acid/ezetimibe (BA/E) in a contemporary and real-world population, enriched for older adults, women, and underrepresented racial/ethnic groups, of adults with a recent acute coronary syndrome (ACS) event independent of use of statin therapy before the ACS event.

Key Dates

Start date
Mar 31, 2022
Status verified
Mar 2022
Primary completion
Jun 30, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Intervention
    Bempedoic acid 180 mg/ezetimibe 10 mg
  • Placebo Comparator: Placebo
    Matching placebo

Primary Outcome Measure

To evaluate the efficacy of BA/E vs. matching placebo on LDL-C level following a recent ACS event. [ Time Frame: 0-12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Kaiser Permanente Northern California Division of ResearchOaklandCalifornia94612
Rachel C Thomas, RN
[email protected]
510-891-3858
Andrew P Ambrosy, MD (PRINCIPAL_INVESTIGATOR)
Alan S Go, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oakland, CA

By research site
Kaiser Permanente Northern California Division of Research· Oakland, CA

Related Studies